Meeting
2017 Gastrointestinal Cancers Symposium
Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b.
Authors
Drew W. Rasco
South Texas Accelerated Research Therapeutics, San Antonio, TX
Drew W. Rasco , Christine Peterson , Ely Benaim , Jaime R. Merchan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02030067
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 445)
DOI
10.1200/JCO.2017.35.4_suppl.445
Abstract #
445
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
RX3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer—Preliminary results of stage II of the phase Ia/IIb study.
First Author: Vincent M. Chung
Poster
2019 Genitourinary Cancers Symposium
Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.
First Author: Nicholas Salgia
Poster
2018 ASCO Annual Meeting
Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).
First Author: Jacob Adashek
Poster
2022 ASCO Annual Meeting
A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01).
First Author: Gang Jin